Therapeutic Asset Ratings

151 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Eflornithine Cancer	Aminex Therapeutics, Inc.	P1/2	CCC (49)
Fuzuloparib Cancer	Tulane University	P1/2	CCC (49)
Ibrutinib Cancer	Jennifer Woyach	P1/2	CCC (49)
Zeprumetostat Cancer	Tulane University	P1/2	CCC (49)
[18F]Fluoropivalate Cancer	University College, London	P2	CCC (48)
Adapt-001 Cancer	EpicentRx, Inc.	P2	CCC (48)
Allogeneic Tumour Lysate Cancer	Elios Therapeutics, LLC	P2	CCC (48)
Cordycepin Cancer	Second Affiliated Hospital of Soochow University	P2	CCC (48)
Dfn-15 Cancer	Emory University	P2	CCC (48)
Firi-Cel Cancer	CARGO Therapeutics	P2	CCC (48)
Isatuximab Cancer	UNC Lineberger Comprehensive Cancer Center	P2	CCC (48)
Lomustine Cancer	Actuate Therapeutics Inc.	P2	CCC (48)
Lorlatinib Cancer	Strata Oncology	P2	CCC (48)
Marijuana Cancer	University of Manitoba	P2	CCC (48)
Prag-1 Cancer	Second Affiliated Hospital of Soochow University	P2	CCC (48)
ts-1 Cancer	National University Hospital, Singapore	P2	CCC (48)
Tumor Lysate, Particle Only Vaccine Cancer	Elios Therapeutics, LLC	P2	CCC (48)
Tuvonralimab Cancer	Second Affiliated Hospital of Nanchang University	P2	CCC (48)
Amxt1501 Cancer	Aminex Therapeutics, Inc.	P1/2	CC (47)
Inkmune Cancer	Inmune Bio, Inc.	P1/2	CC (47)
ELRAGLUSIB Cancer	Actuate Therapeutics Inc.	P2	CC (46)
egf816 Cancer	Cancer Research UK	P2/3	CC (46)
IMA401 Cancer	Immatics Biotechnologies GmbH	P1/2	CC (46)
SIMVASTATIN Cancer	Danae Hamouda, MD	P1	CC (45)
68Ga-grazytracer Cancer	Peking University Cancer Hospital & Institute	P1/2	CC (44)

Showing 51 to 75 of 151 assets